UNSPSC 51312209: Cyproheptadine hydrochloride sesquihydrate

This classification denotes a histamine-1 receptor antagonist with the molecular formula 2C21H21N.2ClH.3H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier NJ82J0F8QC, chemically known as piperidine, 4-(5h-dibenzo(a,d)cyclohepten-5-ylidene)-1-methyl-, hydrochloride, hydrate (2:2:3), but more generally known as cyproheptadine hydrochloride sesquihydrate, which bears US NIH Compound Identifier 6441505.

European Medicines Agency schedules cyproheptadine hydrochloride sesquihydrate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06875MIG. Most nations, for tariff purposes, schedule cyproheptadine hydrochloride sesquihydrate under HS 29333999. SMILES: CN1CCC(=C2C3CCCCC3C=CC4C2CCCC4)CC1.CN1CCC(=C2C3CCCCC3C=CC4C2CCCC4)CC1.O.O.O.CL.CL.

UNSPSC 51312209 Cyproheptadine hydrochloride sesquihydrate is a Commodity code for a specific pharmaceutical active ingredient, but the recent state and local contract opportunities tagged under this code show little alignment with the nominal scope. Seminole County, Florida's IFB60459723LAS solicitation (posted June 30, 2026, due July 26, 2023) procures naloxone and drug deactivation systems for community health initiatives—a different pharmaceutical product class entirely. The Texas Health and Human Services Commission's RFI HHS0017013 (posted April 3, 2026) explores direct-to-manufacturer prescription fulfillment models and pharmacy benefit structures, not individual active pharmaceutical ingredients. The Minnesota Multistate Cooperative Purchasing Alliance's RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products requires manufacturers to supply identified drugs through AmerisourceBergen, Cardinal Health, and Morris & Dickson wholesalers with specific NDC codes and pricing formats, but does not isolate cyproheptadine hydrochloride sesquihydrate as a line item. The mismatch between the code's specific chemical designation and the broad or misaligned scope of recent opportunities suggests this code either sees minimal targeted activity or is assigned inconsistently by issuing bodies.

State and local procurement under this code does not consolidate around a particular geographic region or issuing-body type based on recent activity. The opportunities span a state health agency (Texas HHS), a county public health function (Seminole County), and a multi-state cooperative purchasing vehicle (Minnesota). The absence of multiple solicitations for the same active ingredient, the presence of opportunities tagged to the code that address wholly different pharmaceutical categories or contracting models, and the lack of repeat buyer activity indicate that this Commodity code does not support a coherent or active procurement stream at the state and local level as of mid-2026.